Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Kim SJ, et al. Among authors: lehembre f. Clin Cancer Res. 2015 Oct 15;21(20):4630-41. doi: 10.1158/1078-0432.CCR-14-3195. Epub 2015 Jun 23. Clin Cancer Res. 2015. PMID: 26106074 Free PMC article.
Metastatic disease: a drug discovery perspective.
Lehembre F, Regenass U. Lehembre F, et al. Semin Cancer Biol. 2012 Jun;22(3):261-71. doi: 10.1016/j.semcancer.2012.03.005. Epub 2012 Mar 30. Semin Cancer Biol. 2012. PMID: 22484560 Review.
Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.
Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, Maya M, Zhang F, Wu Q, Lehembre F, Regenass U, Fidler IJ. Kim SJ, et al. Among authors: lehembre f. Neoplasia. 2011 Feb;13(2):167-79. doi: 10.1593/neo.10806. Neoplasia. 2011. PMID: 21403842 Free PMC article.
26 results